论文部分内容阅读
目的：探讨Bevacizumab对人高转移肝癌模型ICI—D20血管形成的抑制作用。方法：分别采用空白对照及Bevaci—zumab治疗LCI—D20,用药28d后处死裸鼠,测量肿瘤质量,检测肿瘤组织微血管密度。结果：对照组肿瘤负荷平均为2．0 g；MVD(microvascular density,微血管密度)平均39．6个/HP；治疗组平均肿瘤负荷为0．1g及平均MVD为4．9个/HP,与对照组比较有显著差异(P＜0．05)。结论：Bevacizumab有抑制肝癌血管形成及肿瘤生长的活性。
Objective: To investigate the inhibitory effect of Bevacizumab on the ICI-D20 angiogenesis in human highly metastatic hepatocellular carcinoma model. Methods: LCI-D20 was treated with Bevaci-zumab as blank control and Bevaci-zumab respectively. The nude mice were sacrificed after 28 days. The tumor mass was measured and the microvessel density was measured. Results: The average tumor burden in the control group was 2.0 g. The average microvascular density (MVD) was 39.6 / HP. The average tumor burden was 0.1 g and the average MVD was 4.9 / HP in the treatment group There was significant difference between the control group (P <0.05). Conclusion: Bevacizumab can inhibit the angiogenesis and tumor growth of hepatocellular carcinoma.